Evaluation of Solid Tumor Patients Presenting with Denovo Bone Marrow Metastasis
Open Access
- 31 December 2023
- journal article
- research article
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 7 (3) , 344-349
Abstract
Aim: Although solid tumors are known to metastasize to the bone marrow, it is rare to be diagnosed with bone marrow involvement. In our study, we aimed to contribute to the literature by evaluating the treatment results and follow-up processes of different solid tumors metastatic to bone marrow in denovo. Material and Methods: We retrospectively analyzed 28 patients who underwent bone marrow biopsy with a prediagnosis of hematologic malignancy and were diagnosed with carcinoma metastasis. Clinicopathologic features, antitumor treatments, treatment-related hematologic toxicities and factors affecting survival were evaluated. Results: Of the 28 patients included in the study, 14 (50.0%) were female and 14 (50.0%) were male. The median age of the patients was 62 years (28-82). Eight patients (28.6%) were diagnosed with breast (28.6%), six with gastric (21.4%), four with lung (14.3%), two each with colon and prostate ca (7.1%), and the primary tumor site could not be determined in six patients (21.4%). Progression was observed in four (40.0%) of the 10 patients with the first series of treatment, three (30.0%) patients had stable response and three (30.0%) patients had partial response. The median progression-free survival time was 130 days (3-494 days) in patients who received first line treatment. The median overall survival time was 26 days (0-1183 days). Thrombocytopenia (p<0.05), hypofibrinogenemia (p<0.05), and poor performance score (p<0.05) were associated with lower survival. Conclusion: Solid tumor patients diagnosed with denovo bone marrow metastases have a very poor prognosis. Additional poor prognostic factors in these patients include thrombocytopenia, hypofibrinogenemia, poor performance status. Accurate and rapid diagnosis of the primary solid tumor through bone marrow biopsy can help establish an appropriate treatment approach focused on the primary carcinoma Amaç: Solid tümörlerin kemik iliği metastazı yaptığı bilinmesine rağmen kemik iliği tutulumu ile tanı almaları nadir görülmektedir. Çalışmamızda denovo kemik iliği metastatik farklı solid tümörlerin tedavi sonuçları ve takip süreçlerini değerlendirerek literatüre katkı sağlamak amaçlanmıştır Gereç ve Yöntemler: Hematolojik malignite ön tanısı ile kemik iliği biyopsisi yapılan ve karsinom metastazı tanısı alan 28 hasta retrospektif olarak incelendi. Hastaların klinikopatolojik özellikleri, aldıkları antitümör tedaviler, tedavi ilişkili hematolojik toksisiteleri ve sağkalımlarına etki eden faktörler değerlendirildi. Bulgular: Çalışmaya dahil edilen 28 hastanın 14'ü (%50,0) kadın, 14'ü (%50,0) erkekti. Hastaların median yaşı 62 (28-82) idi. Hastaların sekizi (%28,6) meme, altısı mide (%21,4), dördü akciğer (%14,3), ikişer (%7,1) tanesi de kolon ve prostat ca (%7,1) tanısı almış olup altı hastanın (%21,4) primer tümör bölgesi belirlenememiştir. Tedavi verilen 10 hastanın dört tanesinde (%40,0) ilk seri tedavi ile progresyon gözlenmiş olup, üç hastada (%30,0) stabil, üç (%30,0) hastada parsiyel tedavi yanıtı elde edilmiştir. İlk seri tedavi alan hastalarda progresyonsuz sağkalım süresi median 130 gün (3-494 gün) gözlenmiştir. Hastaların median genel sağkalım süresi 26 gündür (0-1183 gün). Trombositopeni (p<0,05), hipofibrinojenemi (p<0,05) ve kötü performans skoru (p<0,05) daha düşük sağkalımla ilişkili bulunmuştur. Sonuç: Denovo kemik iliği metastazı ile tanı alan solid tümor hastalarının prognozu çok kötüdür. Bu hastalardaki ek kötü prognostik faktörler arasında trombositopeni, hipofibrinojenemi, kötü performans durumu sayılabilir. Kemik iliği biyopsisi yoluyla primer solid tümörün doğru ve hızlı teşhisi ile primer karsinom üzerine odaklanan uygun bir tedavi yaklaşımının oluşturulmasına yardımcı olabilirKeywords
This publication has 9 references indexed in Scilit:
- Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortalityBlood Advances, 2021
- Clinical outcome of 30 patients with bone marrow metastasesJournal of Cancer Research and Therapeutics, 2018
- Bone Marrow Involvement in Non-Hematological Malignancy: A Clinico-pathological Study From a Tertiary HospitalAnnals of Pathology and Laboratory Medicine, 2018
- Metastatic Bone Marrow Tumors Manifested by Hematologic Disorders: Study of Thirty-Four Cases and Review of LiteratureJournal of Analytical Oncology, 2014
- Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow MetastasesAsian Pacific Journal of Cancer Prevention, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Clinical Outcome of Gastric Cancer Patients with Bone Marrow MetastasesOncology, 2007
- The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: A clinical study of 19 casesBMC Cancer, 2005
- Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast CancerJournal of Clinical Oncology, 2003